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Abstract 
Blood coagulation is essential for physiological hemostasis, but simultaneously 
contributes to thrombotic disease. However, molecular and cellular events controlling initiation 
and propagation of coagulation are still incompletely understood.  Here we demonstrate an 
unexpected role of eosinophils during plasmatic coagulation, hemostasis and thrombosis. 
Using a large-scale epidemiological approach, we identified eosinophil cationic protein (ECP) 
as independent and predictive risk factor for thrombotic events in humans. Concurrent 
experiments showed that eosinophils contributed to intravascular thrombosis by exhibiting a 
strong endogenous thrombin-generation capacity, which relied on the enzymatic generation 
and active provision of a pro-coagulant phospholipid-surface enriched in 12/15-lipoxygenase 
(12/15-LO)-derived hydroxyeicosatetraenoic acid-phosphatidylethanolamines. Our findings 
reveal a previously unrecognized role of eosinophils and enzymatic lipid oxidation as 
regulatory elements that facilitate both hemostasis and thrombosis in response to vascular 
injury, thus identifying promising new targets for the treatment of thrombotic disease. 
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Introduction 
The coagulation cascade represents an evolutionary highly conserved process that 
enables efficient hemostasis in response to vascular injury. An aberrant intravascular 
activation of the coagulation cascade, however, causes thrombotic disease including 
myocardial infarction, ischemic stroke or deep-venous thrombosis, and thus represents the 
leading cause of death worldwide (Stevens et al., 2009). Both hemostasis and thrombosis 
involve the initial formation of a yet unstable platelet aggregate at the site of vascular injury 
(Wolberg, 2007). The subsequent activation of plasmatic coagulation results in the formation 
and polymerization of fibrin, an insoluble protein which allows growth and stabilization of the 
developing thrombus. Initiation of the coagulation cascade essentially relies on the presence 
of a pro-coagulant phospholipid surface and the glycoprotein tissue factor (TF) (Nemerson, 
1968). These two components initiate the sequential assembly and activation of the 
membrane-associated prothrombinase complex (factor Xa and factor Va) (Nemerson, 1968), 
which generates thrombin, the serine protease that converts fibrinogen to fibrin and thereby 
provides the backbone of the growing thrombus (Wolberg, 2007).  
Although all cellular membranes contain abundant amounts of phospholipids, they are 
usually inert and do not support coagulation. Platelets are considered to serve as a major 
source of pro-coagulant phospholipids as these cells can actively modify their membrane, and 
oxidize and externalize the aminophospholipids phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) (O'Donnell et al., 2014; Suzuki et al., 2010; Thomas et al., 2010; 
Yang et al., 2012). Although platelets can potentially acquire TF via leukocyte-derived 
microparticles, they lack endogenous expression of TF (Bouchard et al., 2010). These 
findings raise the question about the exact mechanisms and cells that initiate the assembly of 
the prothrombinase complex during the onset of coagulation and the propagation of 
intravascular thrombosis (Flaumenhaft, 2014).     
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Here, we report that thrombotic events in humans are associated with an in increase in 
the eosinophilic activation marker eosinophil cationic protein (ECP). Subsequent experiments 
showed that eosinophils were abundantly found in thrombi that formed upon vascular injury in 
mice, where these cells critically contributed to thrombin formation and thrombus stabilization 
as well as to physiological hemostasis. Eosinophils exerted a strong endogenous thrombin-
generation capacity that relied on the simultaneous expression of TF and the provision of a 
pro-coagulant phospholipid surface that was enriched in 12/15-lipoxygenase (12/15-LO)-
derived oxidized phospholipids. In accordance, we observed a diminished thrombus formation 
and defective hemostatic response in mice carrying a global or an eosinophil-specific deletion 
of 12/15-LO.  
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Results  
Elevation of eosinophil activation markers predicts the onset of cardiovascular events 
To elucidate mechanisms that trigger thrombotic events during cardiovascular disease 
in humans, we made use of the prospective population-based Bruneck Study (Stegemann et 
al., 2014). This study allows unique monitoring of atherosclerosis progression and 
differentiates between early atherosclerosis, advanced atherosclerotic lesions and the 
occurrence of thrombotic events such as stroke and myocardial infarction. In contrast to early 
atherosclerosis, which primarily reflects a chronic inflammatory intima-thickening, both 
development of advanced atherosclerotic lesions and especially the occurrence of thrombotic 
events are primarily associated with factors reflecting enhanced plaque vulnerability and a 
pro-coagulant state (Willeit et al., 2000). We therefore sought to identify novel serologic 
markers that specifically predict the occurrence of advanced atherosclerotic lesions and 
thrombotic events, respectively. A proteomic proximity ligation assay unexpectedly identified 
an increased plasma level of ECP as highly significant predictor of new-onset 
atherothrombotic events and development of advanced atherosclerotic lesions (Fig. 1A-B). In 
contrast, ECP levels were unrelated to early plaque development and growth and showed 
only weak correlations with age and other vascular risk factors (Fig. 1B-D). These findings 
were robust to multivariable adjustment and stable in sensitivity analyses (Fig. 1C-D). We 
additionally measured ECP levels in two independent cross-sectional cohorts of patients 
suffering from acute arterial or venous thrombotic events, which showed elevated ECP levels 
during acute myocardial infarction and deep venous thrombosis, respectively (Fig. 1E-F). 
Since plasma ECP levels serve as potential marker for eosinophil activation, the data of all 
three cohorts were suggestive of a contribution of eosinophils to thrombus formation and 
vessel occlusion.    
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Eosinophils promote intravascular thrombin formation and thrombus growth 
Immunofluorescence microscopy of experimentally-induced thrombi indeed confirmed 
enrichment of eosinophils, which accumulated at the boarder of platelet-rich areas throughout 
the thrombus (Fig. 2A-B and suppl. fig. 1A-E). To determine whether eosinophils actively 
contributed to the formation of an intravascular thrombus, we consequently performed an 
injury-induced venous thrombosis model of the inferior venae cava (IVC) in two different 
eosinophil-deficient mouse strains namely ΔdblGATA1 mice (Yu et al., 2002) and PHIL mice 
(Lee et al., 2004), as well as in their wild-type (WT) littermates. Absence of eosinophils 
resulted in a dramatically attenuated thrombus formation (Fig. 2C-D), which supported a 
functional contribution of these cells. Also WT mice that had received an eosinophil-depleting 
anti-SiglecF antibody showed a significantly decreased thrombotic potential (Fig. 2E and 
suppl. fig. 1F).  
As these data pointed towards a so far unrecognized role of eosinophils during the 
initiation and/or propagation of thrombosis, we sought to elucidate the underlying 
mechanisms. We did not observe alterations in platelet numbers or platelet function or any 
intrinsic defects of clotting factors in eosinophil deficient mice (Suppl. fig. 2A-C). However, 
measurement of plasmatic thrombin-antithrombin (TAT) complexes as quantitative marker for 
thrombin generation, showed that TAT complexes rapidly appeared after induction of 
thrombosis in WT mice, but were almost absent in eosinophil-deficient mice (Fig. 2F). These 
data were indicative of a major contribution of eosinophils to the initiation of plasmatic 
coagulation and the intravascular generation of thrombin in response to vascular injury. As 
thrombin-mediated blood coagulation is considered essential for the stabilization of the initial 
platelet aggregate and thrombus growth (Wolberg, 2007), we consequently used intravital 
video-microscopy to visualize platelet aggregation and thrombus formation upon vascular 
injury in the mouse carotid artery of WT and eosinophil-deficient mice. Whereas an absence 
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of eosinophils did not impair the formation of a first platelet-rich aggregate at the site of injury, 
it provoked a rapid dissolution of this yet unstable initial thrombus (Fig. 2G and supplementary 
movies 1-4). In line with these findings, we observed an exacerbated blood loss in eosinophil-
deficient ΔdblGATA1 mice after a medium-scale injury (15 mm tail cut) (Fig. 2H), indicative of 
a defective coagulation-dependent secondary hemostasis. Platelet-dependent primary 
hemostasis after small-scale injury (3 mm tail cut) was unaffected by the absence of 
eosinophils (Suppl. fig. 2D). Platelet depletion, in turn, unmasked the defective hemostasis in 
ΔdblGATA1 mice after the small-scale injury, which was depicted by a dramatically 
augmented blood-loss (suppl. fig. 2E-F) and thus demonstrated that platelets and eosinophils 
performed synergistic roles during thrombosis and hemostasis. Notably, absence of 
eosinophils did not impair thrombus development in the IVC upon flow restriction (Suppl. fig. 
2G), suggesting that this leukocyte subset specifically mediated the hemostatic and 
thrombotic response upon vascular injury, but did not contribute to stasis-induced thrombus 
formation.  
 
Eosinophils autonomously generate thrombin in a TF-dependent manner 
Together our data revealed a key role of eosinophils during injury-induced thrombin 
generation and blood coagulation in vivo. Consequently, we determined whether these cells 
were able to autonomously generate thrombin in the absence of exogenous pro-coagulant 
phospholipids or recombinant TF. We found that in vitro-differentiated murine eosinophils as 
well as isolated human eosinophils indeed exerted a dramatic endogenous thrombin 
generation potential, which was further augmented by pre-stimulation of eosinophils with ADP 
or collagen (Fig. 3A-B). Thrombin generation was preceded by formation of FXa and followed 
by the appearance of fibrin clots (Fig. 3C-D and suppl. fig. 3A). These data indicated the 
involvement of a TF-dependent pathway and suggested that eosinophils were equipped with 
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all necessary key components for the initiation of plasmatic coagulation, which would include 
an endogenous provision of TF and pro-coagulant phospholipids. We confirmed expression of 
TF by eosinophils, which were additionally able to expose this glycoprotein on their surface 
upon ADP stimulation (Fig. 3E-F and suppl. fig. 3B). Addition of a blocking antibody against 
TF abrogated eosinophil-induced thrombin generation, confirming the functional involvement 
of this glycoprotein (Fig. 3G).  
 
Eosinophils actively provide a pro-coagulant phospholipid surface that supports TF-
mediated thrombin generation 
The thrombin generation potential of activated eosinophils was clearly superior to other 
TF-expressing cells such as LPS-stimulated macrophages (Suppl. fig. 3C). These findings 
suggested that additional factors allowed eosinophils to efficiently promote coagulation. As 
the TF-mediated generation of thrombin is considered to depend on the presence of a pro-
coagulant phospholipid surface (Mackman, 2004; Nemerson, 1968), we determined whether 
eosinophils underwent specific changes within their plasma membrane that would support 
plasmatic coagulation. The aminophospholipids PS and PE can facilitate thrombin generation, 
but are usually hidden within the inner leaflet of the plasmamembrane and thus unavailable 
for an interaction with plasmatic coagulation factors (Thomas et al., 2010; Yang et al., 2012). 
Measurement of Annexin-V surface binding, a surrogate marker for the exposure of 
aminophospholipids (Clark et al., 2013), revealed a rapid increase in the Annexin-V positivity 
of eosinophils in response to ADP, indicating that these cells actively changed the polarity of 
their plasmamembrane (Fig. 4A). Exposure of PE and PS species was additionally confirmed 
using mass spectrometry (Fig. 4B). Masking of surface aminophospholipids by Annexin-V, on 
the other hand, blocked the ADP-induced thrombin-generation in a dose-dependent manner 
(Fig. 4C), confirming an essential role of these events during eosinophil-induced coagulation.  
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In platelets, translocation of PS and PE was shown to involve the activity of Ca2+-
sensitive Cl- channels of the TMEM family that were suggested to additionally control 
cationic currents and seem to either possess or induce scramblase activity at the plasma 
membrane (Kunzelmann et al., 2014; Suzuki et al., 2010; Tian et al., 2012; Yang et al., 
2012). Also eosinophils expressed several TMEM family members (Suppl. fig. 3D) and the 
Ca2+ ionophore A23187 rapidly triggered exposure of the aminophospholipids PE and PS 
in eosinophils (Fig. 4D and suppl. fig. 3E). Intracellular chelation of Ca2+ by BAPTA/AM or 
addition of Tannic acid, a non-selective inhibitor of the TMEM family of calcium-activated 
Cl- channels, in turn, interfered with the ADP-induced binding of Annexin-V to their surface 
(Fig. 4E). In line with these findings, ADP stimulation of eosinophils triggered a rapid and 
transient increase in cytosolic Ca2+ levels in a Ca2+-free environment, which could be 
boosted by the addition of extracellular calcium (Fig. 4F). Prior depletion of intracellular 
calcium stores by Thapsigargin, an inhibitor of the endoplasmatic reticulum Ca2+ ATPase, 
blocked the initial ADP-induced increase in cytosolic Ca2+ (Fig. 4G). These data were 
suggestive of an initial ADP-induced Ca2+ release from intracellular stores and a 
subsequent activation of a store-operated calcium entry through the plasma membrane 
(Bergmeier et al., 2013) that triggered exposure of pro-coagulant aminophospholipids to 
immediately support TF-dependent formation of the prothrombin complex (Fig. 4H).   
 
12/15-LO-mediated formation of pro-coagulant oxidized phospholipids essentially 
contributes to the thrombin-generation potential of eosinophils  
Next we aimed to determine if specific aminophospholipid species accounted for the 
increased thrombin-generation potential of eosinophils and performed an additional lipidomic 
analysis of their phospholipid profile, which showed that their cellular membranes were 
enriched in a specific set of PE oxidation products (12-hydroxyeicosatetraenoic acid-PEs; 12-
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HETE-PEs) (Fig. 5A). Since oxidation of phospholipids had been suggested to increase their 
pro-coagulant potential (Thomas et al., 2010), we sought to determine a potential role of PE-
oxidation and the different oxidized PE-species during eosinophil-mediated thrombin 
generation. 12-Lipoxygenase (12-LO; Alox12) and 12/15-lipoxygenase (12/15-LO; Alox15) 
are the two major enzymes exerting 12-lipoxygenase activity in mammals (Kuhn et al., 2015) 
and thus served as the potential enzymatic source for the identified 12-HETE-PEs in 
eosinophils. Analysis of peripheral blood leukocytes and platelets showed that Alox12 was 
absent in all leukocyte subsets and exclusively expressed in platelets. Alox15 mRNA and 
12/15-LO protein, in turn, were highly expressed in mouse and human eosinophils, but absent 
in platelets, monocytes, neutrophils or the healthy vascular wall (Fig.5B-D and suppl. fig. 4A). 
These data showed that, during the steady state, eosinophils were the only cells expressing 
Alox15 within the peripheral blood and the vasculature. 12/15-LO expression was accordingly 
absent in blood leukocytes of 12/15-LO-deficient (Alox15-/-) and eosinophil-deficient 
ΔdblGATA1 mice (Fig. 5E-F). Mass spectrometry showed that Alox15-/- eosinophils indeed 
lacked the identified 12-HETE-PEs, thus confirming 12/15-LO as the single enzymatic source 
of these oxidized aminophospholipids in eosinophils (Fig. 5G).  
In accordance with a major contribution of 12/15-LO-mediated membrane oxidation to 
the thrombin-formation activity of eosinophils, we observed a severely reduced ability of 
Alox15-/- eosinophils to generate thrombin and FXa as well as to induce fibrin clots (Fig. 5H-I 
and suppl. fig. 4B). The 12/15-LO inhibitor Baicalein potently interfered with the pro-coagulant 
activity of mouse and human eosinophils as well (Fig. 5H-J), showing that the Alox15-
mediated control of plasma coagulation by eosinophils represented an evolutionary 
conserved mechanism and potential target for pharmacologic intervention during thrombotic 
disease. Of note, 12/15-LO-deficient eosinophils showed no alterations in their eosinophil 
maturation markers (Suppl. fig. 5A-B). Phospholipase A2 (PLA2)-dependent cleavage of 
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12/15-LO products from membrane phospholipids was not involved in the 12/15-LO-mediated 
thrombin generation activity of eosinophils, as inhibition of PLA2 activity did not reduce the 
pro-coagulant activity of eosinophils (Suppl. fig. 5C)    
We subsequently measured thrombin generation in the presence of liposomes 
containing different PE species to substitute for 12/15-LO-activity. Addition of liposomes with 
12-HETE-PE immediately restored the thrombin-generation potential of Alox15-/- eosinophils, 
whereas identical liposomes with non-oxidized PEs were ineffective (Fig. 5K), supporting the 
concept of a 12/15-LO-mediated control of thrombin generation that was dependent on 
generation and provision of 12-HETE-PEs.  
 
12/15-LO expression in eosinophils promotes thrombotic disease and supports 
physiological hemostasis 
To determine the in vivo relevance of 12/15-LO-mediated membrane oxidation by 
eosinophils during thrombotic disease, we performed an injury-induced thrombosis model in 
Alox15-/- mice and their WT littermates. In line with our previous data, absence of 12/15-LO 
resulted in reduced TAT complex formation (Fig.6A) and an impaired thrombus formation 
(Fig. 6B). Alox15-/- mice accordingly displayed a defective hemostatic response (Fig. 6C), 
although these animals showed no alterations in the function and number of platelets or in 
plasmatic coagulation factors (Suppl. fig. 6A-C). We subsequently confirmed a reduced 
thrombotic potential of mice carrying a conditional deletion of Alox15 in eosinophils as well as 
in animals that had received Baicalein, demonstrating a key role of the identified pathway 
during coagulation in vivo and highlighting its potential as therapeutic target (Fig. 6D-E).  
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Discussion 
Until recently, eosinophils were solely envisaged as driving force of parasite defense 
and as mediators of allergic disease (Jacobsen et al., 2012). However, an increasing amount 
of data suggests a broader and rather homeostatic role of these cells during the resolution of 
inflammation and regulation of tissue repair (Heredia et al., 2013; Lee et al., 2010; 
Rothenberg and Hogan, 2006; Tani et al., 2014). More recently, eosinophils were also 
described to accumulate in human thrombi (Riegger et al., 2015) and reported to express TF 
(Moosbauer et al., 2007). Moreover, activated eosinophils were shown to tether to 
immobilized platelets under shear flow (McCarty et al., 2003), a mechanism which might 
explain their homing to the freshly formed and yet instable thrombus. Clinical data show that 
hypereosinophilic patients indeed suffer from an increased incidence of atypical thrombotic 
events (Ames et al., 2010; Todd et al., 2014). Although these findings have indicated a 
potential role of this leukocyte subset during thrombus formation, functional evidence that 
support a direct contribution of eosinophils to thrombosis or hemostasis as well as insights 
into involved molecular pathways have been lacking so far. Our current data show that 
eosinophils critically contribute to thrombin formation and plasmatic coagulation, a process 
which is often regarded as the most primitive form of immune response to tissue injury and 
infection (Engelmann and Massberg, 2013). Other leukocyte subsets have been previously 
implicated as potential source of TF and might likewise contribute to thrombus formation in 
certain settings (Engelmann and Massberg, 2013; von Bruhl et al., 2012). However, 
neutrophils and monocytes in peripheral blood seem to be unable to provide an enzymatically 
engineered, pro-coagulant phospholipid-surface, whereas platelets express pro-thrombotic 
phospholipids but lack intrinsic TF expression. Eosinophils thus seem to combine the abilities 
of platelets to oxidize and expose distinct pro-thrombotic aminophospholipids with the 
capacity of leukocytes to provide TF within a single cell (Fig. 6F). Notably, neutrophils were 
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shown to contribute to stasis-induced thrombosis, but are fully dispensable during hemostasis 
after  vascular injury (Engelmann and Massberg, 2013). Eosinophils, in turn, seem to primarily 
mediate the hemostatic and thrombotic response that follows tissue injury, suggesting that 
different leukocyte subsets fulfill distinct tasks during hemostasis and thrombosis, 
respectively.   
On a molecular level, we identify murine 12/15-LO and its human orthologue 15-LO as 
key enzymes during the generation of pro-coagulant phospholipids in eosinophils and show 
that this pathway directly contributes to the initiation of thrombus formation after injury. While 
12/15-LO expression in macrophage-derived foam cells has been previously implicated in the 
oxidation of LDL-particles and the formation of atherosclerotic plaques (Cyrus et al., 2001; 
Uderhardt and Kronke, 2012), the physiological role of 12/15-LO-mediated lipid oxidation has 
remained unclear (Kuhn and O'Donnell, 2006). Our findings suggest that 12/15-LO-mediated 
enzymatic lipid oxidation serves as a key mechanism controlling eosinophil-directed 
coagulation and physiologic hemostasis. Our current data thus provide an explanation for the 
stringent conservation of this enzymatic pathway during mammalian evolution and 
simultaneously suggest that eosinophils as well as 12/15-LO are promising new targets for an 
anti-coagulant therapy.  
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 Figure legends  
 
Figure 1. Elevation of eosinophilic cationic protein serves as a marker for 
cardiovascular disease in humans  
(A, B) Forest plots of the prospective association of baseline eosinophil cationic protein (ECP) 
with (A) events of cardiovascular disease (CVD) and (B) early and advanced atherosclerosis 
in the Bruneck Study (follow-up 2000 to 2010). All analyses were adjusted for age, sex, and 
prior CVD. Analyses focusing on ultrasound endpoints were adjusted to the extent of baseline 
atherosclerosis (log-transformed atherosclerosis summation score).  Squares and lines 
represent hazard ratios of events and 95% confidence intervals. Hazard ratios were derived 
from Cox Regression models and calculated for a 1-SD higher level of ECP. Composite CVD 
events considered ischemic strokes, medical record-confirmed TIAs, myocardial infarctions 
and vascular deaths. The extended CVD events additionally considered revascularization 
procedures.  
* This analysis is confined to 277 individuals free of atherosclerosis at baseline and focused 
on the manifestation of first carotid plaques.   
† This analysis considers all 558 individuals with ultrasound follow-up and focused on the 
manifestation of new carotid plaques.  
‡ This analysis considers all 558 individuals with ultrasound follow-up and focused on both the 
manifestation of new carotid plaques and extension of existing ones.  
§ This analysis considers all 558 individuals with ultrasound follow-up and focused on the 
development of advanced complicated plaques (stenosis >40 %). The second line is confined 
to 269 subjects with manifest baseline atherosclerosis. 
(C) Odds ratios / hazard ratios and 95 % confidence intervals derived from Logistic regression 
and Cox regression models and calculated for a 1-SD higher level of ECP. The composite 
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cardiovascular disease (CVD) endpoint included ischemic strokes, medical-record-confirmed 
TIAs, myocardial infarctions, and vascular deaths.  
* Multivariable models were additionally adjusted for hypertension, smoking (pack-years), 
diabetes, loge-transformed C-reactive protein, body-mass index, LDL- and HDL-cholesterol. 
† Models with extended adjustment additionally included HbA1c, platelet and lymphocyte 
count. 
(D) Correlation pattern of eosinophil cationic protein (ECP) level with blood cell counts, 
demographic and vascular risk factors in the Bruneck Study (evaluation 2000, n=682 
including 354 women and 328 men). GFR, glomerular filtration rate; BP, blood pressure; high-
sensitivity C-reactive protein (hs-CRP); LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; 
HbA1c, glycated hemoglobin. Spearman correlation coefficients are given for all variables. 
Correlations that are statistically significant after correction for multiple comparisons 
(Bonferroni-corrected P value <0.05) are in bold and corresponding squares have covering 
colours.  
(E, F) ELISA of human ECP in serum of controls (n=15) and patients diagnosed with (e) acute 
myocardial infarction (AMI; n=75). (c) ELISA of ECP in plasma of controls (n=20) and (f) 
patients diagnosed with deep venous thrombosis (DVT; n=41).  
 
Figure 2. Eosinophils contribute to intravascular thrombosis and hemostasis  
(A) Representative microscopy image (n=5) showing immunofluorescence staining for 
platelets (CD41; green), eosinophils (CCR3; red) and cellular nuclei (DAPI; blue) in a ferric 
chloride (FeCl)-induced thrombus of a mouse inferior vena cava (IVC). White arrows indicate 
CCR3+ eosinophils, dotted lines mark lacunae surrounded by platelet aggregates. (B) 
Relative number of eosinophils in IVC thrombi of wild-type (WT) mice compared to peripheral 
blood counts (n=5). (C, D) FeCl-induced IVC thrombus of (C) ΔdblGATA1 mice (BALB/c 
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background; n=4), (D) Phil mice (C57BL/6 background; n=10) and their corresponding WT 
littermates. (E) FeCl-induced IVC thrombosis in WT mice treated with anti-SiglecF antibody 
(n=4) or isotope control. (F) Measurement of thrombin-antithrombin complexes (TAT) in 
plasma from dblGATA1 mice (n=5) after FeCl-induced IVC thrombosis. (G) Representative 
image of a FeCl-induced thrombosis of the carotid artery in WT or ΔdblGATA1 mice (30 
minutes after FeCl-induced injury) and quantification of the kinetic of thrombus formation and 
dissolution, respectively (right; see also supplementary movies) (n=4). (H) Bleeding assays 
(15 mm tail cut) with wild-type (BALB/c; n=5) and ΔdblGATA1 mice (n=9 and 5, respectively). 
Bar graphs show relative weight loss, OD575nm of the lost blood after lysis as and primary 
bleeding time (time until the first stop of bleeding). 
 Data are representative of at least three independent experiments.  Error bars represent 
SEM*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test.  
 
Figure 3. Eosinophils autonomously initiate thrombin generation  
(A, B) Calibrated thrombin generation curve of (A) in vitro-generated mouse eosinophils or 
(B) human eosinophils after stimulation with ADP and/or collagen. Bar graphs show 
endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; nM). 
(C) Calibrated factor Xa generation curve of mouse eosinophils. (D) Plasma clotting time 
experiments with in vitro-generated mouse eosinophils stimulated with ADP or collagen. Bar 
graphs display calculated clotting index, black bar shows plasma with ADP alone. (E) (left) 
qRT-PCR analysis of tissue factor mRNA (F3) expression in mouse monocytes, neutrophils, 
eosinophils and platelets; expression of gene of interest was normalized to Atcb expression. 
(right) Western blot analysis of tissue factor protein (47-kDa) expression in sorted mouse 
leukocytes. (F) Flow-cytometry analysis of the exposure of tissue factor on the surface of 
resting or ADP-stimulated mouse eosinophils. Histograms show representative flow 
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cytometric stainings, bar graphs show mean geometric fluorescence intensities (gMFI). (G) 
Calibrated thrombin generation assay with ADP-stimulated mouse eosinophils in the 
presence of blocking anti-tissue factor antibody or isotope control. Bar graphs (right) show 
endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; nM). 
Data are representative of at least three independent experiments.  Error bars represent 
SEM*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test. 
 
Figure 4. Ca2+-dependent exposure of aminophospholipids by eosinophils promote 
thrombin generation 
(A) Flow-cytometry analysis of the binding of Annexin-V (AxV) to aminophospholipids on the 
surface of resting or ADP-stimulated mouse eosinophils. Histograms show representative 
AxV stainings, bar graphs show mean geometric fluorescence intensities (gMFI). (B) 
LC/MS/MS-based quantification of the exposure of the aminophospholipids 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) in mouse eosinophils in 
response to ADP stimulation. (C) Calibrated thrombin generation assays with resting or ADP-
stimulated mouse eosinophils in the presence of Annexin V (AxV). Bar graphs (right) show 
endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; nM). 
(D) Flow-cytometry analysis of Annexin V-binding on mouse eosinophils over time in the 
presence of calcium ionophore A23187, ADP or vehicle. (E) Flow-cytometry analysis of 
Annexin V-binding on mouse eosinophils in the presence of Tannic acid or intracellular Ca2+-
chelator BAPTA/AM. Bar graphs show geometric mean fluorescence intensity. (F) Flow-
cytometry based analysis of intracellular Ca2+ signaling, indicated by Fluo3/FuraRed-ratio, 
over time in Ca2+-free environment. Where indicated, CaCl2 at a final concentration of 1 mM 
was added. (G) Flow-cytometry based analysis of intracellular Ca2+ signaling, indicated by 
Fluo3/FuraRed-ratio, over time in Ca2+-free environment.  
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(H) Postulated mechanism of a sequential generation and Ca2+-dependent externalization of 
aminophospholipids at the surface of eosinophils. 
 
Figure  5. 12/15-LO-mediated oxidation of membrane phospholipids initiates 
eosinophil-mediated thrombin formation  
(A) Representative LC/MS/MS analysis of different 12-HETE-PE oxidation species in lipid 
extracts of in vitro-generated mouse eosinophils. (B) Quantitative PCR with reverse 
transcription (qRT-PCR) analysis of 12/15-lipoxygenase mRNA (Alox15) and 12-lipoxygenase 
mRNA (Alox12) in mouse monocytes (CD11b+CD115+), neutrophils (CD11b+Ly6G+; PMN), 
eosinophils (SSChiCD11b+Siglec-F+) and platelets after fluorescence-activated cell sorting 
(FACS); expression was normalized to Atcb expression. (C) Western blot of 12/15-LO protein 
(74 kDA) expression in wild-type (WT) and Alox15-/- mouse eosinophils. (D) qRT-PCR 
analysis of Alox5 and Alox15 mRNA (top) and western blot analysis of 15-LO protein (bottom) 
expression in human neutrophils (huPMN) and human eosinophils (huEos) isolated by Ficoll 
density gradient centrifugation and magnetic cell separation; mRNA expression was 
normalized to Actb. (E) Flow-cytometry analysis of 12/15-LO in eosinophils (SSchiSiglecF+) 
isolated from peripheral blood of WT and Alox15-/- mice. (F) Flow-cytometry analysis of the 
SSchi12/15-LO+ population in blood from WT, Alox15-/- and ΔdblGATA1 mice. (G) LC/MS/MS-
based quantification of different esterified 12- and 15-HETE-PE, non-esterified 5-, 8-, 11-, 12- 
and 15-HETE species, and prostaglandins D2 and E2 in wild-type (blue) and Alox15-/- (red) 
mouse eosinophils. Levels are presented as nanogramm per 1x106 cells. (H) Calibrated 
thrombin generation curve of mouse wild-type (WT) eosinophils, eosinophils treated with 
Baicalein and Alox15-/- eosinophils. Bar graphs (right) show endogenous thrombin potential 
(ETP; nM*min) and peak of thrombin generation (peak; nM). (I) Plasmatic clotting time 
experiments with WT mouse eosinophils, mouse eosinophils treated with the 12/15-LO-
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inhibitor Baicalein and Alox15-/- mouse eosinophils. Bar graphs display calculated clotting 
index, black bar shows plasma with ADP alone. (J) Calibrated thrombin generation assay with 
lysates generated from human eosinophils in the presence of PRP-reagent (see methods). 
Bar graphs (right) show endogenous thrombin potential (ETP; nM*min) and peak of thrombin 
generation (peak; nM). (K) Calibrated thrombin generation assays with WT and Alox15-/- 
mouse eosinophils in the presence of PC/PS-liposomes carrying oxidized 12-HETE-PE or 
non-oxidized PE (SAPE) species as indicated. Bar graphs (right) show endogenous thrombin 
potential (ETP; nM*min) and peak of thrombin generation (peak; nM). Data are representative 
of at least three independent experiments.  Error bars represent SEM*P < 0.05, **P < 0.01, 
***P < 0.001; Student’s t test.    
 
Figure  6. 12/15-LO-induced coagulation contributes to thrombus formation and 
hemostasis   
(A) TAT complex formation (n=6) and (B) thrombus formation (n=4) after ferric chloride 
(FeCl)-induced thrombosis of the inferior venae cava (IVC) in Alox15-/- mice (C57BL/6 
background) and WT littermates. (C) Bleeding assays (15 mm tail cut) with wild-type 
(C57BL/6) mice, Alox15-/- mice and wild-type mice treated with Baicalein (each n=6). Bar 
graphs show relative weight loss, OD575nm of the lost blood after lysis and primary bleeding 
time (time until first stop of bleeding). (D, E) FeCl-induced IVC thrombus formation in (D) mice 
carrying an eosinophil-specific deletion of Alox15 (Alox15fl/fl; n=10) and their WT littermates 
(Alox15+/+; n=9) and (e) mice that received the 12/15-LO inhibitor Baicalein (n=4) and a 
vehicle (n=4), respectively. Data are representative of at least three independent 
experiments.  Error bars represent SEM*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test. 
(F) Proposed mechanism of the eosinophil-mediated and 12/15-LO-induced thrombin 
generation in response to platelet aggregation. 
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Online material and methods 
 
Patient cohorts. 
Bruneck Study population  
The Bruneck Study is a prospective population-based survey on the epidemiology and 
pathogenesis of atherosclerosis, which started in 1990. The study population was 
recruited as a sex- and age-stratified random sample of all residents aged 40 to 79 living 
in Bruneck (n = 4739), Northern Italy. The present analysis focuses on the third 
quinquennial follow-up examination of 6824 subjects and a 10-year follow-up period 
(2000 - 2010). The study protocol was approved by the Ethics Committees of Verona 
and Bolzano, and all participants gave their written informed consent before entering the 
study. 
All risk factors were assessed by means of validated standard procedures described 
previously (Kiechl et al., 2002; Kiechl et al., 2013; Stegemann et al., 2014). In brief, body 
mass index was calculated as weight divided by height squared (kg/m2). Hypertension 
was defined as blood pressure ≥ 140/90 mm Hg (mean of three independent readings 
obtained with a standard mercury sphygmomanometer after at least ten minutes of rest) 
or the use of anti-hypertensive drugs. Lifetime smoking was assessed as pack-years. 
Diabetes was defined based on ADA criteria.  
The composite CVD endpoint was composed of ischemic stroke, medical record-
confirmed TIA, myocardial infarction, and vascular death. A total of 102 individuals 
experienced primary outcome events. The extended composite endpoint additionally 
considered revascularization procedures, which increased the number of individuals 
affected to 118.  Myocardial infarction was deemed confirmed when World Health 
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Organization criteria for definite disease status were met. Ischemic stroke and transient 
ischemic attack (TIA) were classified according to the criteria of the National Survey of 
Stroke. A TIA was considered only if the diagnosis could be made with high accuracy 
(medical record-confirmed TIA). Vascular mortality included deaths from ischemic 
stroke, myocardial infarction, rupture of aortic aneurysms and sudden cardiac deaths. All 
revascularization procedures (angioplasty and surgery) were carefully recorded. 
Ascertainment of events or procedures did not rely on hospital discharge codes or the 
patient’s self-report but on a careful review of medical records provided by the general 
practitioners, death certificates, and Bruneck Hospital files, and the extensive clinical 
and laboratory examinations performed as part of the study protocols. Major advantages 
of the Bruneck Study are that virtually all subjects living in the Bruneck area were 
referred to the local hospital and that the network existing between the local hospital and 
the general practitioners allowed retrieval of practically all medical information on 
persons living in the area.  
 
Assessment of atherosclerosis: At each study visit, participants underwent bilateral 
carotid duplex sonography using a 10-MHz transducer and a 5-MHz Doppler. All 
subjects were examined in supine position. The scanning protocol involved four 
segments of the right and left carotid artery: proximal common carotid artery (15 to 30 
mm proximal to the carotid bulb), distal common carotid artery (<15 mm proximal to the 
carotid bulb), proximal internal carotid artery (carotid bulb and the initial 10 mm of the 
vessel), distal internal carotid artery (>10 mm above the flow divider). A plaque was 
defined as a focal structure encroaching into the arterial lumen with a thickening of the 
vessel wall of at least 0.5 mm relative to surrounding segments. The maximum axial 
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diameter of plaques (in millimeters) was assessed on the near and far walls at each of 
the eight vessel segments. The atherosclerosis summation scores was calculated by 
summing all diameters (intra-observer coefficient of variation, 13,5 %, n = 100). 
A person-based atherosclerosis progression model (Kiechl and Willeit, 1999a; Kiechl 
and Willeit, 1999b) was developed and validated in the Bruneck Study that allowed 
differentiation between early and advanced stages in atherosclerosis development: 
(Kiechl et al., 2013) Early atherosclerosis subsumes  the manifestation of new plaques 
and/or nonstenotic progression of existing plaques. Main characteristics are a slow and 
continuous plaque growth usually affecting more than one plaque simultaneously and 
accompanied by a compensatory or even over-compensatory enlargement of the vessel 
at the plaque site. The term “incipient atherosclerosis” was used for the development of 
first plaques in subjects free of atherosclerosis at baseline(Kiechl et al., 2002).  
Advanced complicated atherosclerosis was assumed when the relative increase in the 
maximum plaque diameter exceeded twice the measurement error for the method 
(internal carotid artery, 25 %; common carotid artery, 17 %) and a lumen narrowing of at 
least 40% was achieved. This process is featured by a usually solitary prominent 
increase in plaque size and absence of vascular remodelling thus resulting in significant 
lumen compromise. From a mechanistic perspective it refers to plaque destabilization 
and subsequent atherothrombosis (Willeit et al., 2000).  
The two progression categories were highly reproducible [kappa coefficients > 0.8 (n = 
100)]. 
Risk profiles differ significantly between the two stages of carotid artery disease with 
early atherosclerosis relying on standard risk factors and advanced atherosclerosis 
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being mainly related to markers reflecting plaque vulnerability or enhanced 
prothrombotic activity (Kiechl et al., 2007; Willeit et al., 2000).  
 
Statistical methodology: Cox proportional hazard models with progressive adjustment 
were used to assess whether baseline ECP was associated with new-onset CVD. We 
detected no departure from the proportional hazards assumption by inspecting 
Schoenfeld residuals and checking the parallelity of log-log survival plots. Associations 
between ECP and the various measures of atherosclerosis were tested by means of 
logistic regression analysis. All reported P values are two-sided.  
 
Proteomic serum analysis: Blood samples were drawn in the year 2000 after an 
overnight fast and 12 hours of abstinence from smoking 1-3 and immediately frozen and 
stored at -70° C (without any thawing-freezing cycle). Laboratory parameters were 
measured by standard assays and a blood differential was performed using an 
automated analyzer (Kiechl et al., 2002; Kiechl et al., 2013; Stegemann et al., 2014). 
Eosinophil cationic protein (ECP) was measured in plasma samples collected in year 
2000 as part of a novel proteomics chip (Proximity Extension Assay,4 Proseek Multiplex 
CVD I96x96, Olink Bioscience, Uppsala, Sweden) as described before (Assarsson et al., 
2014).     
   
AMI Cohort 
Patients were enrolled at the Universitätsklinikum Erlangen. All patients with AMI fulfilled 
the ESC guidelines criteria for STEMI. We enrolled only patients, who underwent 
coronary angiography. In addition, for the respective controls, we included patients with 
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an invasive exclusion of coronary artery disease. All patients and controls were of 
German descent. 
Exclusion criteria for our study were congestive heart failure, aortic dissection, aortic 
valve disease, hypertrophic cardiomyopathy, peri-/myocarditis, pulmonary embolism, 
apical ballooning syndrome, hypertensive crisis, acute neurological disease, or anemia. 
On admission, blood was drawn for routine laboratory and study analysis. Detailed 
patients’ history and informed consent was obtained from all patients. The study was 
approved by the institutional ethics committee for human subjects at the Medical Faculty 
of the University Erlangen-Nuremberg.  
 
DVT Cohort 
All patients with DVT suffered acute unprovoked DVT and were diagnosed at the 
outpatient department of the Division of Angiology of the Medical University of Vienna. 
Diagnosis of DVT was confirmed in all patients by color duplex sonography. Exclusion 
criteria were active malignancy, life expectancy <2 years, ongoing anticoagulant 
treatment and age <18 years. 
 
Animals.  
Animal experiments were approved by the government of Mittelfranken, the Mayo Clinic 
and the Ludwig Maximilian University, Munich, respectively. 12/15-LO-deficient (Alox15-/-
; C57BL/6 background), ΔdblGata1 (BALB/c background) and PHIL mice were 
described previously (Lee et al., 2004; Yu et al., 2002). ΔdblGata1mice carry a deletion 
of a high-affinity GATA-binding site in the GATA-1 promoter (∆dblGATA-1 mice), 
whereas PHIL mice express a diphtheria toxin A transgene that is driven by a fragment 
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of the eosinophil peroxidase promoter. Both mouse strains show a selective and 
complete absence of the eosinophilic lineage. To achieve an eosinophil-specific deletion 
of Alox15, we crossed a EPX-Cre mouse (Doyle et al., 2013) with mice carrying floxed 
Alox15 alleles (both C57BL/6 background) (Cole et al., 2012). Experiments were 
performed at an age of 8-10 weeks. While experiments with ∆dblGATA-1 mice were 
performed in hemizygous mutant males and wild-type male littermates, respectively, the 
experiments with other mouse strains were performed with an equal gender distribution 
of mutant and wild-type mice.    
Animal experiments were performed by a blinded investigator.  
 
Cell culture.  
Eosinophils were generated from bone marrow isolated from 8-week-old mice as 
previously described (Dyer et al., 2008) with minor modifications. In brief, bone marrow 
was incubated in RPMI (Gibco) containing 20% heat-inactivated feral calf serum (FCS), 
25 mM HEPES, 100 IU/ml Penicillin (Gibco), 10 µg/ml Streptomycin (Gibco), 2 mM 
glutamine (Gibco), 1x NEAA (Sigma), 1mM Sodium pyruvate (Sigma), 50 µM β-
mercaptoethanol (Gibco), 100 ng/ml mFLT3L (Peprotech) and 100 ng/ml mSCF 
(Peprotech) for 4 days, followed by 10 days differentiation with 10 ng/ml IL-5 
(Peprotech). Half of the medium was changed every other day. Maturation was 
monitored by flow-cytometry of SiglecF and CCR3 expression. Fully matured eosinophils 
were used after 14 days of total culture. For thrombin generation assays, RAW 264.7 
mouse macrophages were treated with 100 ng/ml LPS in RPMI containing 10% FCS for 
24 hrs.  
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Plasma clotting time.  
Human standard citrate plasma (Siemens Healthcare) was freed from residual cellular 
and sub-cellular particles by ultracentrifugation, and supplemented with 10% rat plasma 
(GeneTex). Plasma clotting time with or without addition of eosinophils was 
automatically recorded after re-calcification with 20 µl star-tem (ROTEM; Tem 
International GmbH) using a ball coagulometer (BC1; SYCOmed) at 37 °C. When 
indicated, eosinophils were stimulated with 40 µM ADP (Roche) or 20 µg/ml collagen 
(Roche) for 10 minutes at 37 °C prior re-calcification. Clotting index was calculated as 
follows: clotting time [sec.]-1 x 100.  
 
Calibrated thrombin and Factor Xa generation.  
Thrombin generation was performed on a Fluoroskan Ascent FL (Thermo Scientific) by 
using a Filter pair with excitation 390 nm and emission 460 nm. To each well of a 96-well 
plate containing 80 µl of eosinophils (250.000 cells) resuspended in plasma (10% rat / 
90% human), 20 µl of trigger solution (PBS or ADP or collagen and/or phospholipids) 
was added and incubated for 10 minutes at 37 °C. End concentration of ADP (Roche 
Diagnostics) was 40 µM. Then 20 µl of re-calcification solution containing a fluorogenic 
substrate for thrombin (Z-Gly-Gly-Arg) was automatically added. α2-macroglobulin-
thrombin was used separately for calibration according to the manufacturer’s 
specifications. Factor Xa generation was performed equally, but with the fluorogenic 
substrate Pefafluor FXa (Loxo GMBH) and a filter pair with excitation 340 nm and 
emission 440 nm.  When indicated, eosinophils were pretreated with 1 µM Baicalein 
(Merck Millipore) or DMSO control, and 40 µg/ml anti-mouse coagulation factor III/tissue 
factor antibody (AF3178; R&D Systems) or isotype control (normal goat IgG; AB-108-C; 
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R&D Systems) for 1 hour at 37 °C prior to stimulation, respectively. For thrombin 
generation with platelet-rich or platelet-poor plasma, PRP-reagent (final concentration 
0,5 pM tissue factor; Cat# TS42.00; Thrombinoscope) or PPP-reagent (final 
concentration 5 pM tissue factor and 4mM phospholipids; Cat# TS30.00; 
Thrombinoscope) was added according to the manufacturer’s specifications. Data were 
evaluated using Thrombinoscope 5.0 software (Thrombinoscope).  
 
Calcium signaling. 
500.000 cells were stained with 6 μM Fluo-3 (Invitrogen) and 12 μM FuraRed 
(Invitrogen) in 200 μl staining buffer (RPMI; 10 mM HEPES; 2 % FCS) for 45 minutes at 
37 °C with gentle agitation. Cells were subsequently washed twice in Ca2+-free Tyrode’s 
buffer (134 mM NaCl; 12 mM NaHCO3; 2,9 mM KCl; 0,34 mM Na2HPO4; 1,0 mM MgCl2; 
10 mM HEPES; 5 mM HEPES; 0,5 % BSA; pH 7,4) and incubated for 20 minutes at 
room temperature in the dark. Where indicated, CaCl2 was added to final concentration 
of 1 mM. Calcium signaling experiments were performed at room temperature with a 
Gallios flow-cytometer (Beckman Coulter) recording the Fluo-3/FuraRed-ratio over time. 
Data were analyzed using FloJo software. Reagents used: BAPTA/AM and thapsigargin 
(Calbiochem), Tannic acid and A23187 (Sigma). 
 
Antibodies.  
Rat anti-mouse SiglecF PE (E50-2440; BD Pharmingen); rabbit polyclonal anti-12 
Lipoxygenase (ab23678; Abcam), rabbit anti-mouse Tissue Factor (EPR8986; Abcam); 
polyclonal goat anti-mouse Coagulation Factor III/Tissue Factor antibody (R&D 
Systems; #AF3178); goat anti-rabbit Cy5 or Cy3 (Dianova); anti-mouse CD11b PE/Cy7 
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(M1/70), anti-human CD16 FITC (3G8), anti-mouse Ly6G FITC (1A8), anti-mouse CD41 
PE or APC (MWReg30), anti-mouse CD115 PE or APC (AFS98), anti-mouse CD45 
APC/Cy7 (30-F11), anti-mouse CD16/32 (TruStain fcXTM), Annexin-V FITC and DAPI-
staining were purchased from BioLegend. 
 
Fluorescence activated cell sorting and flow-cytometry.  
Bone marrow was isolated from sacrificed wildtype mice, and blood was drawn from the 
vena cava inferior of anaesthetized mice, using a syringe (23 G needle) containing 10 % 
0,1 M sodium citrate. Red blood cells were gently lysed with ice-cold distilled water. 
Cells were pelleted and resuspended in buffer (1x PBS containing 0,5 % BSA and 2 mM 
EDTA). After Fc receptor blockade, cells were stained with antibodies as indicated. For 
intracellular staining of 12/15-LO in blood leukocytes, cells were fixed and permeabilized 
prior to staining using a intracellular staining kit (00-5523; eBioscience). Fluorescence 
activated cell sorting (FACS) was performed on a MoFlo XDP (Beckman Coulter), flow-
cytometry was performed on a Gallios (Beckman Coulter). Data were analyzed using 
FloJo software (Tree Star). Platelet counts were recorded from citrated whole blood with 
an Adivia 120 cytometer (Siemens Healthcare). 
 
Immunofluorescence microscopy.  
For microscopy, thrombi were only partially dissected from the vessels to increase 
stability during preparation of the histological sections. Samples were embedded in 
Tissue-Tek O.C.T compound (Sakura), snap-frozen and stored at -80 °C. 4 µm 
cryosections were fixated and permeabilized with ice-cold acetone and stored at -20 °C 
until staining. Slides were stained with indicated antibodies (dilution 1:100) and analyzed 
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on an ECLIPSE Ni-U (Nikon). Pictures were processed using NIS-Elements BR4.0 
(Nikon). For quantification of eosinophils in mouse thrombi, we analyzed thrombi of 3 
independent experiments (4 slides per individual thrombus).  
 
Isolation of platelets and generation of platelet-rich (PRP) and platelet-poor 
plasma (PPP).  
To avoid artificial platelet activation, blood was carefully drawn from the vena cava 
inferior of anaesthetized mice, using a syringe (23 G needle) containing 10 % 0,1 M 
sodium citrate. To isolate platelets, a same volume of EHS-buffer (150 mM NaCl, 1 mM 
EDTA, 10 mM HEPES) was added to the citrated blood, followed by two 20 minutes 
centrifugations (50 g). Platelets were pelleted (5 minutes, 300 g) and resuspended in 
HBSA-buffer (20 mM HEPES, 100 mM NaCl, 1 mg/ml BSA) for further analyzis. PRP 
was generated out of citrated plasma by 10 minutes centrifugation (50 g) and diluted to 
140 cells/nl with autologous plasma, PPP was generated by two 10 minutes 
centrifugations (1500 g). 
 
Isolation of human eosinophils.  
Blood was drawn from healthy, non-atopic volunteers into syringes containing 10 % 0,1 
M citrate, and immediately processed. Cells were separated by Ficoll gradient 
centrifugation (Lymphoflot #824012; Biorad) according to the manufacturer’s 
specifications. From now on, all procedures were performed at 4 °C. The granulocyte-
rich red pellet was subsequently lysed using ice-cold distilled water. Untouched 
eosinophils were isolated using a commercially available eosinophil isolation kit (130-
092-010; Miltenyi Biotec) according to the manufacturer’s specifications. Purity of 
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enriched eosinophils was evaluated by flow-cytometry of side scatter and CD16 
expression. Cells were resuspended in RPMI containing 10 % FCS, and stimulated with 
ADP or Baicalein for 30 minutes at 37 °C. Then cells were washed, resuspended in 
HBSA-buffer and cell lysates were generated by three repeated freeze-thaw cycles. 
Samples were stored at -80 °C until further analysis. 
 
Western blotting.  
Cells were washed twice with PBS and then lysed in RIPA-buffer (50 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1 % TritonX-100, 1 % Sodium deoxycholate, 0,1 % SDS) containing 
1 % protease/phosphatase inhibitor (P9599; Sigma) and 1 mM PMSF (Active Motif) for 
30 minutes on ice. Aortas were rinsed three times with PBS containing 1000 IE heparin, 
cut into little pieces and digested in serum-free DMEM containing 2 mg/ml collagenase 
type 2 (Worthington) for 1 hour at 37 °C, and then lysed in RIPA-buffer for 30 minutes on 
ice. Protein content was assessed using PierceTM BCA Protein Assay Kit (Thermo 
scientific) according to the manufacturer’s specifications. Protein extracts were 
separated by SDS-PAGE using a 10 % SDS-polyacrylamide gel, transferred to a Trans-
Blot Nitrocellulose membrane (BioRad) and immunoblotted overnight in TBST containing 
5 % non-fat dry milk with following antibodies: rabbit polyclonal anti-12 Lipoxygenase 
(ab23678; Abcam; dilution 1:1000), mouse coagulation factor III/tissue factor antibody 
(#AF3178; R&D Systems; dilution 1:200), rabbit anti-mouse β-actin (clone AC-74, 
Sigma-Aldrich, dilution 1:1000). As positive control for tissue factor expression, lysates 
of LPS-treated RAW 264.7 mouse macrophages were used. As positive control for 
12/15-LO, murine resident macrophages were isolated from peritoneal cavity of C57BL/6 
mice by lavage, plated in RPMI and washed thoroughly after 1 hour to remove any non-
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adherent cells. After overnight culture in RPMI containing 10 % FCS, cells were lysed in 
RIPA buffer and stored on -20 °C until further analysis. 
 
Real-time PCR analysis.  
RNA was isolated with peqGOLD TRIFast (peqlab) and 500 ng of total RNA was reverse 
transcribed with human leukemia virus reverse transcriptase using the Gene Amp RNA 
PCR kit (Applied Biosystems) and oligo(dT) primers. For qRT-PCR after fluorescence 
activated cell sorting, leukocyte subpopulations were directly sorted into lysis buffer and 
RNA isolation was performed with RNeasy Mini Kit (Qiagen) including DNA digestion 
(DNase I, #EN0521; Fermentas) according to the manufacturer’s specifications. 
Quantitative real-time PCR was performed using a LightCycler instrument and SYBR 
Green I kit (Roche Diagnostics). We normalized the ratio of mRNA expression of the 
gene of interest to the mRNA expression for house-keeping genes Actb or Gapdh (with 
comparable results); depicted if not otherwise stated are the results for normalization to 
Actb (2-▵Ct). For detection of tissue factor mRNA two different primer pairs were used 
with comparable results; depicted in the paper are the results for primer pair #1. Used 
PCR primer sequences for mouse mRNA: 
 Actb 
  for 5’-TGTCCACCTTCCAGCAGATGT-3’ 
  rev 5’-AGCTCAGTAACAGTCCGCCTAGA-3’ 
 Gapdh 
  for 5’-CTACACTGAGGACCAGGTTGTCT-3’ 
  rev 5’-CAGGAAATGAGCTTGACAAAGTT-3’ 
 Alox5 
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  for 5’-ATTGCCATCCAGCTCAACCA-3’  
  rev 5’-ACTGGAACGCACCCAGATTT-3’  
 Alox12 
  for 5’-CGCTGTTGCCACCATGAGAT-3’ 
  rev 5’-ATGAGCTGGGTCCGCGTTC-3’  
 Alox15 
  for 5’-CTCTCAAGGCCTGTTCAGGA-3’ 
  rev 5’-GTCCATTGTCCCCAGAACCT-3’ 
 Ccr3 
  for 5’-ACTGGACTCATAAAGGACTTAGCA-3’   
  rev 5’-CCATGACCCCAGCTCTTTGA-3’   
 Epx 
  for 5’-CGCCTGGATAGCCAGTATCG-3’   
  rev 5’-ATGGAATCCTGCCGGTTCAG-3’   
 Siglecf 
  for 5’-TCAGCCCTGAAAGTAGCAGC-3’ 
  rev 5’-TTTGGGTGTCTGGGACTGTG-3’ 
 
 F3 (coagulation factor III; tissue factor) #1 
  for 5’-AGGATGTACCTGGGCCTAT-3’ 
  rev 5’-GGCTGTCCAAGGTTTGTGTC-3’ 
 
 F3 (coagulation factor III; tissue factor) #2 
  for 5’-GAAACTGGAAAAACAAGTGCTTCTT-3’  
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  rev 5’-CCAGGTCACATCCTTCACGAT-3’  
 
Used PCR primer sequences for human mRNA: 
 Alox15 
  for 5’-GTGTCCACTGGGGCCTCGCT-3’ 
  rev 5’-GCGGCCCCAGATACTCCGGTA-3’ 
 Alox5 
  for 5’-GACGTTCACGGCCGAGGTGG-3’ 
  rev 5’-AGCTGGCCGAAGTTGACCGC-3’ 
 Actb 
  for 5’-AGAAAATCTGGCACCACACC-3’ 
  rev 5’-TAGCACAGCCTGGATAGCAA-3’ 
 Gapdh 
  for 5’-TGATGACATCAAGAAGGTGGTGAAG-3’ 
  rev 5’-TCCTTGGAGGCCATGTGGGCCAT-3’ 
 
Lipid extraction.  
1,2-dimyristoyl-PE (DMPE, 10 ng) and 15-HETE-d8 (5 ng), was added to each sample 
before extraction as an internal standard. Hydroperoxides were reduced to the 
corresponding alcohol by adding 1 mM SnCl2 for 10 minutes at room temperature. Lipids 
were extracted by adding 1 M acetic acid, 2-propanol, hexane (2:20:30, vol/vol) to the 
sample at a ratio of 2,5 ml solvent to 1 ml sample, vortexing and then adding 2,5 ml of 
hexane. Following vortexing and centrifugation (1500 rpm, 5 minutes), lipids were 
recovered in the upper hexane layer. The samples were then re-extracted by the 
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addition of an equal volume of hexane followed by further vortexing and centrifugation. 
The combined hexane layers were then dried under vacuum and analyzed for HETE-
PEs and free eicosanoids using LC/MS/MS. 
 
HETE-PE Quantitation using LC/MS/MS.  
Lipids were separated on a C18 Luna, 3 μm, 150 mm x 2 mm column (Phenomenex), 
using a gradient of 50 - 100% B over 10 minutes followed by 30 minutes at 100 % B 
(Solvent A: methanol:acetonitrile:water, 1 mM ammonium acetate, 60:20:20. Solvent B: 
methanol, 1 mM ammonium acetate) with a flow rate of 200 μl/min.  Lipids were 
monitored using multiple reaction monitoring (MRM) mode. Transitions monitored were 
for parent ions of m/z 738.6, 764.6, 766.6 and 782.6 [M-H]- fragmenting to daughter ions 
with m/z 219.2 (15- HETE), 115.1 (5-HETE) or 179.1 (12-HETE). Standard curves were 
generated using internal standards (DMPE), and different synthetic primary standards. 
Products were quantified by LC/MS/MS electrospray ionisation on an Applied 
Biosystems 4000 Q-Trap. Acquisition of product ion spectra was triggered during elution 
of ions of interest, with the instrument operating in ion trap mode. 
 
Free eicosanoid quantitation using LC/MS/MS.  
Lipids were separated on a C18 Spherisorb ODS2 column (150 x 4.6 mm, 5 µm particle, 
Waters Ltd, Elstree, UK) using a gradient of 50–90 % B over 30 minutes, followed by 5 
minutes at 90 % B (A, water : acetonitrile : acetic acid, 75 : 25 : 0.1, B, methanol : 
acetonitrile : acetic acid, 60 : 40 : 0.1) with a flow rate of 1 ml/min. Eicosanoid species 
were monitored with specific parent to daughter ion transitions in negative ion mode 
([M−H]−) for HETEs (m/z 319.2) at 115 (5-HETE), 179.1 (12-HETE), 219 (15-HETE), 
16 
 
155 (8-HETE), 167 (11-HETE). 15-HETE-d8 was monitored at m/z 327 to 226. Products 
were identified and quantified using primary standards and internal standard run in 
parallel under the same method conditions. 
 
Quantification of externalized aminophospholipids 
Externalization of phosphatidylethanolamine and phosphatidylserine species in 
eosinophils was measured according as previously described (Thomas et al., 2014). 
Briefly, cultured murine eosinophils (4x106 per ml) were stimulated with ADP (40 µM) or 
the calcium ionophore A23187 (10 µM ) and treated with EZ-link NHS-biotin or EZ-link 
sulfo-NHS-biotin (Thermo Fisher Scientific) for measuring total cellular lipids and 
external aminophospholipids, respectively by LC/MS/MS. 
 
Generation of liposomes.  
Liposomes used in the thrombin generation experiments contained 20 % of the indicated 
oxidized or un-oxidized phospholipid species, and 75 % PAPC and 5 % PAPS as carrier 
lipids. Phospholipids were solved in methanol or chloroform, and kept under a layer 
Argon on -80 °C until usage.  
Phospholipids used:  
PAPS (110670; Avanti lipids): 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
glycero-3-phospho-L-serine 
PAPE (110638; Avanti lipids): 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
glycero-3-phosphoethanolamine 
PAPC (850459C; Avanti lipids): 1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-
glycero-3-phosphocholine 
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12-HETE-PE: Lipids were generated as previously described (Morgan et al., 2010). 
Indicated phospholipids were added to PAPC/PAPS carrier lipids, before solvent was 
evaporated under a gentle stream of Argon. Phospholipids were resuspended in HBSA-
buffer and generously vortexed. Liposomes were then prepared by 10 freeze-thaw 
cycles and kept on ice before performing the assay.  
 
Tail bleeding assays.  
Two different tail bleeding assays were performed as previously described (Liu et al., 
2012; Rossaint et al., 2013) with minor modifications. Briefly, mice were anaesthetized 
with ketamin (100 mg/kg body weight) and xylazin (20 mg/kg body weight), and placed 
under a heating lamp to maintain constant body temperature of 37 °C. A 3 mm (ca. 1-1,2 
mm diameter) or 15 mm (ca. 2,2-2,5 mm diameter) piece of the tail-tip was cut off with a 
sharp scalpel. The distal 2,5 cm of the bleeding tail was immediately dipped into a 50 ml-
tube filled with pre-warmed 0,9% saline, and the time until cessation of blood flow for 
more than 5 seconds was recorded. If not otherwise stated, bleeding was monitored for 
20 minutes in total to assess re-bleedings due to lacking thrombus stability. The amount 
of lost blood was assessed by comparison of body weight (including tail tip) before and 
after bleeding (relative weight loss). Additionally, the collected blood was lysed and 
OD575nm was recorded, indicating the hemoglobin content of the lost blood. 
 
Injury-related venous thrombosis.  
Thrombosis was induced as described previously  with minor modifications. In brief, 
mice (20-25 g body weight) were anaesthetized with ketamin (100 mg/kg body weight) 
and xylazin (20 mg/kg body weight), and placed under a heating lamp to maintain 
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constant body temperature of 37 °C. A ventral midline incision was performed and the 
intestines were gently put aside. The vena cava inferior was laid free carefully and a 
filter paper (1 mm x 2 mm x 4 mm) soaked with 4 % of aqueous ferric chloride solution 
was placed on top of the vessel. After 3 minutes incubation, the filter paper was 
removed and the peritoneal cavity was thoroughly rinsed with pre-warmed 0,9 % saline. 
After another 30 minutes mice were sacrificed, blood was taken by cardiac puncture, 
and the vena cava containing the thrombus was removed. The clot was dissected free 
from the vessel and prepared under a microscope for further analysis. Wet thrombus 
weight was measured using a precision balance (Sartorius R16P) after removal of 
excess water.  
 
Injury-related arterial thrombosis and intravital microscopy. 
Murine platelets were isolated from whole blood, labeled with 5-carboxy-flourescein 
diacetate succinimidyl ester (DCF) and adjusted to a final concentration of 150 × 106 
platelets / 250 μl. Mice were anesthetized (Medetomidin 0,5 mg/kg body weight; 
Midazolam 5 mg/kg body weight; Fentanyl 0,05 mg/kg body weight), and the platelet 
suspension was injected i.v. via a jugular vein catheter. The contralateral carotid artery 
was prepared under a dissecting microscope (Zeiss), and a filter paper (1 mm x 2 mm x 
4 mm) presoaked in 10 % FeCl3 solution was placed on top of the vessel. After 3 
minutes incubation, the filter paper was removed, and dynamic thrombus formation was 
recorded over time using a high-speed wide-field Olympus BX51WI fluorescence 
microscope equipped with a long-distance condenser and a 20x (NA 0.95) water 
immersion objective, a monochromator (MT 20; Olympus) and a charge-coupled device 
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camera (ORCA-ER; Hamamatsu Photonics). For image acquisition and analysis a 
computer (Dell) with Cell^R (Olympus) software was used. 
 
IVC flow restriction model 
The IVC flow restriction model was previously described in detail (von Bruhl et al., 2012). 
Briefly, a median laparotomy was performed and the IVC was exposed by atraumatic 
surgery. We positioned a space holder (FloppyR II Guide Wire 0.014 in [0.36 mm]; 
Guidant Corporation) on the outside of the vessel and we placed a permanent narrowing 
ligature (8.0 monofil polypropylene filament, Premilene; Braun) exactly below the left 
renal vein. Subsequently, the wire was removed to avoid complete vessel occlusion. 
Side branches were not ligated or manipulated. Flow velocity was determined 
immediately after the flow restriction (Cap-Image 7.1). Because we wanted to rule out 
endothelial injury as a trigger for venous thrombosis, all mice with bleedings or any injury 
of the IVC during surgery were excluded from further analysis. There was no difference 
in the exclusion rate across the different experimental groups. The median laparotomy 
was immediately sutured by a 7.0 polypropylene suture (Ethicon). For weight 
measurement, the vessel was excised just below the renal veins and proximal to the 
confluence of the common iliac veins. After the restriction procedure the blood flow 
velocity was reduced by ∼80 % (Fig. 1 B). The shear stress was 0.144 dyne/cm2 ± 0.02 
SEM before the flow restriction and 0.072 dyne/cm2 ± 0.017 SEM after the procedure in 
the IVC close to the site of ligation. Sham experiments consisted of preparation of the 
IVC and placement of the filament under the vessel without ligation. 
 
Depletion of platelets and eosinophils, and Baicalein treatment.  
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For depletion of eosinophils, 20 μg of purified rat anti-mouse SiglecF (E50-2440; BD 
Pharmingen) or isotype rat IgG2a (BD Pharmingen) in 100 μl sterile PBS was injected 
into the lateral tail vein. Experiments were performed 6 hours after injection. For 
depletion of platelets, anti-platelet antibody (6A6-IgG2a; 0,2 μg/g body weight) or 
isotope IgG2a was injected into the lateral tail vein (both antibodies were kindly provided 
by Falk Nimmerjahn). Experiments were performed 1 hour after injection. Depletion of 
platelets and eosinophils was evaluated by an Advia hematocytometer  or flow-
cytometry, respectively, in separate experiments after indicated time to avoid any 
interference with the in vivo assays by the vascular injury.  
For inhibition of 12/15-LO in vivo, 10 μg/g body weight Baicalein or DMSO control in 200 
μl PBS was injected intraperitoneal two times within 24 hours. Experiments were 
performed 1 hour after last injection. 
 
ELISAs.  
Mouse blood was drawn into syringes containing 10 % 0,1 M citrate, and immediately 
put on ice. Plasma was obtained by 10 minutes centrifugation (3000 g) and stored at -80 
°C until analyzis. Following ELISA kits were used: Mouse TAT Complex ELISA Kit 
(EMT1020-1; Assaypro); Human ECP ELISA Kit (SK00128-01; Aviscera Bioscience); 
ELISAs were performed according to the manufacturer’s specifications.  
 
Statistics.  
Data are shown as means ± SEM. Group mean values from in vivo-experiments were 
compared by unpaired, two-tailed Student's t test, in vitro-experiments were analyzed 
using one-way ANOVA (Bonferroni correction for multiple comparison). If not otherwise 
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indicated, the data shown are representative of at least three experiments producing 
similar results. *** p < 0.001; ** p < 0.01; * p < 0.05. 
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Suppl. Fig. legends 
Suppl. Fig. 1 
 (A) Representative microscopy picture (n=5) showing an annotated, longitudinal section 
of an isolated FeCl-induced thrombus of a mouse inferior vena cava with 
immunofluorescence staining for CD41 (green), CCR3 (red) and DAPI (blue). 
 (B) Representative detail of a venous mouse thrombus stained for CD41 (green), CCR3 
(red), Ly6G (blue) and DAPI (white). Red arrows indicate CCR3+ eosinophils, blue 
arrows indicate Ly6G+ neutrophils. 
(C) Representative detail of a venous mouse thrombus stained for CCR3 (green), major 
basic protein (MBP) (red), DAPI (blue) and CD41 (turquoise). Box indicates MBP+CCR3+ 
eosinophil. 
(D) Representative microscopy picture (n=5) showing a longitudinal section of an 
isolated FeCl-induced thrombus of a mouse inferior vena cava in wild-type and 
eosinophil-deficient PHIL mice (n=5) stained for eosinophil associated ribonuclease 
(EAR; red). 
 (E) Histogram of flow-cytometry analysis of FACS-sorted cells showing CCR3 
expression in monocytes (Monos), neutrophils (PMN) or eosinophils (EOS) in the 
peripheral blood of WT mice. 
(F) Flow-cytometry analysis of peripheral mouse eosinophils (CD11b+SiglecF+) 6 hours 
after intravenous injection of isotope control (left) or anti-SiglecF antibody (E50-2440; 
right). 
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Suppl. Fig. 2 
(A) Platelet counts in peripheral blood from wild-type (n=5) or ΔdblGATA1 mice (n=6). 
(B) Platelet aggregation assay with whole blood from wild-type (n=4) or ΔdblGATA1 
mice (n=4) (thin lines represent standard deviation). 
(C) Parameters obtained from coagulometric assays with platelet-poor (PPP; left) or 
platelet-rich (PRP; right) plasma isolated from BALB/c wild-type (white; n=4) or 
ΔdblGATA1 mice (green; n=4). 
 (D) 3 mm tail cut bleeding assays with wild-type (BALB/c; n=5) and ΔdblGATA1 mice 
(n=9 and 5, respectively). Bar graph shows primary bleeding time (time until the first 
stop of bleeding). 
(E) 3 mm tail cut bleeding assay with wild-type (n=5) or ΔdblGATA1 mice (n=5) after 
platelet depletion by intravenous injection of 6A6 antibody. Bleeding experiments were 
terminated prematurely after 10 minutes. Graphs show bleeding time, relative weight 
loss and OD575nm of the collected blood after lysis. 
Data are representative of at least three independent experiments.  Error bars represent 
SEM*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test. 
(F) Platelet counts in peripheral blood from BALB/c (white; n=5) or ΔdblGATA1 mice 
(green; n=5) after injection of isotype control or 6A6. 
(G) Thrombus weight in wild-type (n=3) or ΔdblGATA1 mice (n=3) upon stasis-induced 
thrombosis in the IVC flow restriction model. 
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Suppl. Fig. 3 
(A) Overlap of the calibrated thrombin and factor Xa generation curves of murine 
eosinophils. 
 (B) Gating strategy for fluorescence activated cell sorting of leukocyte subpopulations 
isolated from bone marrow. Neutrophils were identified as CD45+CD11b+ (not shown) 
Ly6G+Siglec-F-, eosinophils were identified as CD45+CD11b+ (not shown) 
Ly6GSiglecF+, and monocytes were identified as CD45+ (not shown) CD11b+CD115+. 
Percentages indicate purity of sorted population in re-analysis. 
(C) Calibrated thrombin generation assay with ADP-stimulated mouse eosinophils, and 
resting or LPS-treated RAW 264.7 macrophages (RAWMΦ). Bar graphs show 
endogenous thrombin potential (ETP; nM*min) and peak of thrombin generation (peak; 
nM). 
(D) qRT-PCR analyzis of Tmem16a, Tmem16f and Tmem16k expression in sorted 
Mouse leukocyte subsets; expression was normalized to Actb. 
(E) LC/MS/MS-based quantification of the exposure of the aminophospholipids 
phosphatidylethanolamine (PE) and phosphatidylserine (PS) in mouse eosinophils in 
response to stimulation with the Ca2+ ionophore A23187. 
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Suppl. Fig. 4 
(A, top) Western blot analysis of 12/15-LO protein (74 kDa) expression in whole aorta 
lysates from wild-type or Alox15-/- mice, and resident wild-type or Alox15-/- peritoneal 
mouse macrophages (as positive control for 12/15-LO expression). (A, bottom) Flow-
cytometry analysis of 12/15-LO expression in CD31+ endothelial cells in single cell 
suspension generated from whole aorta isolated from wild-type (left) or Alox15-/- mice 
(right). 
(B) Calibrated factor Xa generation curve of mouse wild-type (WT) eosinophils and 
Alox15-/- eosinophils.  
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Suppl. Fig. 5 
(A) qRT-PCR analysis of Alox15 and CCR3 mRNA in mouse eosinophils during 14 days 
of in vitro-differentiation with IL-5; expression normalized to Actb and related to day 0. 
(B) qRT-PCR analyzis of mRNA of lipoxygenase isoforms (Alox5, Alox12, Alox15) 
and eosinophil maturation markers (Ccr3, Epx) in wildtype (WT) and Alox15-/- mouse 
eosinophils; expression normalized to Actb and related to WT mouse eosinophils. 
(C) Calibrated thrombin generation assay with ADP-stimulated mouse eosinophils in the 
absence or presence of indicated concentrations of the phospholipase A2 inhibitor 
AACOCF3. 
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Suppl. Fig. 6 
 (A) Platelet counts in peripheral blood from whole blood from wild-type (C57BL/6) or 
Alox15-/- mice (each n=5). 
(B) Platelet aggregation assay with whole blood from wild-type mice (C57BL/6) or 
Alox15-/- mice (each n=4; thin lines represent standard error). 
(C) Parameters obtained from coagulometric assays with platelet-poor (PPP; left) or 
platelet-rich (PRP; right) plasma isolated from wild-type (white) or Alox15-/- mice 
(red). Each n=4. 
Data are representative of at least three independent experiments.  Error bars represent 
SEM*P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test. 
